Tamibarotene

Phase 2Small molecule

SSyros Pharmaceuticals

Tamibarotene is one of 204 small molecule programs targeting Acute Promyelocytic Leukemia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

203

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Promyelocytic LeukemiaActive, not recruiting

Chronic Myelomonocytic LeukemiaActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Acute Myeloid LeukemiaActive, not recruiting

Lupus NephritisActive, not recruiting

Tropical Spastic ParaparesisActive, not recruiting

Acute Promyelocytic LeukemiaPhase 1

Active, not recruiting

Chronic Myelomonocytic LeukemiaPhase 1/Phase 2

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Acute Myeloid LeukemiaPhase 2

Active, not recruiting

Lupus NephritisPhase 2

Active, not recruiting

Tropical Spastic ParaparesisPhase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Tamibarotene

SSyros Pharmaceuticals

Phase 2

1 2

PORTRAZZA

Eli Lilly

Preclinical

8 3

Lenvima

Eisai

Preclinical

6 4

Imjudo

AstraZeneca

Preclinical

5 5

Gilotrif

Boehringer Ingelheim

Preclinical

12 6

Ofev

Boehringer Ingelheim

Preclinical

7 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Completed·SSyros Pharmaceuticals·Phase 2·NCT02807558·155 enrolled

Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome

Terminated·SSyros Pharmaceuticals·Phase 3·NCT04797780·246 enrolled

Lupus Nephritis1 trial

Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis

Unknown status·KKinki University·Phase 2·NCT01226147·20 enrolled

Relapsed or Refractory1 trial

Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL

Completed·CCytRx·Phase 2·NCT00520208·15 enrolled

Non-Small Cell Lung Cancer1 trial

First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer

Terminated·CCytRx·Phase 2·NCT01337154·140 enrolled

Acute Promyelocytic Leukemia1 trial

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Terminated·NNorthwestern University·Phase 1·NCT00985530·4 enrolled

5 more indications

Tropical Spastic Paraparesis1 trial

Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)

Unknown status·—·Phase 2/3·NCT01343355·15 enrolled

Acute Myeloid Leukemia1 trial

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Terminated·SSyros Pharmaceuticals·Phase 2·NCT04905407·66 enrolled

ADPKD1 trial

Study of Tamibarotene in Patients With ADPKD

Active, not recruiting·RRege Nephro Co., Ltd.·Phase 2·NCT06289998·70 enrolled

Alzheimer's Disease1 trial

Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease

Unknown status·OOsaka City University·Phase 2·NCT01120002·50 enrolled

Chronic Myelomonocytic Leukemia1 trial

Phase I/II Study of SY-1425 (Tamibarotene) in Combination With Azacitidine and Venetoclax for Patients With Chronic Myelomonocytic Leukemia

Withdrawn·MM.D. Anderson Cancer Center·Phase 1/2·NCT06085638

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Tamibarotene. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tamibarotene compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tamibarotene. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Syros Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSyros Pharmaceuticals

Tamibarotene

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myelodysplastic Syndrome2 trials

Lupus Nephritis1 trial

Relapsed or Refractory1 trial

Non-Small Cell Lung Cancer1 trial

Acute Promyelocytic Leukemia1 trial

Tropical Spastic Paraparesis1 trial

Acute Myeloid Leukemia1 trial

ADPKD1 trial

Alzheimer's Disease1 trial

Chronic Myelomonocytic Leukemia1 trial

References

Drug Info

Quick Facts

Related News